Adaptimmune And Astellas Team Up For Off-The-Shelf T-Cell Therapies
Could Be Worth $900m
Executive Summary
News of the deal emerged as the UK firm's shares skyrocketed after its SPEAR T-cell platform delivered responses in four solid tumor types.
You may also be interested in...
Adaptimmune/Genentech Deal Gives Powerful Push To Solid Tumor Cell Therapies
Adaptimmune is getting a leg up in the race to develop iPSC-derived allogeneic cell therapies in a deal with the Roche subsidiary worth potentially more than $3bn.
ASCO: Presentations Showcase Possibilities Of Next-Generation Cell Therapies
An education session looked at ways researchers are hoping to make cell therapies more applicable in solid tumors.
Adaptimmune ‘Neck And Neck’ For First Solid Tumor T-Cell Therapy Nod For Afami-Cel
The company’s CEO and chief medical officer talked about some challenges as well as opportunities and what they have learned from the experience of other cell therapies.